Cartesian Therapeutics’ (RNAC) Buy Rating Reiterated at Needham & Company LLC
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued on Thursday,Benzinga reports. They presently have a $41.00 price objective on the stock. Needham & Company LLC’s price target points to a potential upside of 159.49% from the stock’s […]
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued on Thursday,Benzinga reports. They presently have a $41.00 price objective on the stock. Needham & Company LLC’s price target points to a potential upside of 159.49% from the stock’s […]
